Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated

Wondering which stocks to invest in right now? According to the following five-star Wall Street analysts, the stocks listed below are worth buying ...

Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM – Research Report) and Vertex Pharma...

Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Vertex Pharmaceuticals (VRTX)

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $414.00. Wang covers the Healthcare s...

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $525.00. The company’s shares closed...

Vertex Pharmaceuticals (VRTX) Receives a Buy from TD Cowen

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $414.00. The company’s shares closed ...

Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc. ( ($VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented ...

Vertex Pharmaceuticals Reports Strong Q3 2025 Results

Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is conducting a Phase 3 clin...

Vertex Pharmaceuticals Advances Cystic Fibrosis Treatment with New Pediatric Study

Vertex Pharmaceuticals Advances Sickle Cell Disease Treatment with Exa-cel Study

Vertex Pharmaceuticals Inc. (($VRTX)) announced an update on their ongoing clinical study. Vertex Pharmaceuticals Inc. is conducting a Phase 1/2 cl...

Vertex Pharmaceuticals Advances VX-670 Study for Myotonic Dystrophy Type 1

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $471.00. The company’s share...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VRTX	$426.76	+1.05%	1.92M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VRTX	$426.76	+1.1%	1.92M
3
4
5
6

VRTX

VRTX

Get Vertex Pharmaceuticals Incorporated Data in Excel

Get Vertex Pharmaceuticals Incorporated Data in Excel